Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
MREO | US
0.11
2.56%
Healthcare
Biotechnology
30/06/2024
04/10/2024
4.40
4.40
4.50
4.32
Mereo BioPharma Group plc a biopharmaceutical company develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate etigilimab (OMP-313M32) an antibody T-cell immunoreceptor with Ig and ITIM domains which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83) which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197) a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649) an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition it develops rare disease product candidates including Setrusumab (BPS-804) a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966) an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate etigilimab; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London the United Kingdom.
View LessPositive Momentum
Strength based on increasing price with high volume
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Strong Sharpe Ratio (> 1.2)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
33.9%1 month
65.2%3 months
55.5%6 months
62.4%-
-
8.10
0.08
0.06
-1.21
555.68
-
-37.31M
676.95M
676.95M
-
-3.79K
-
-
-48.47
5.01
3.50
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
0.56
Range1M
0.84
Range3M
1.67
Rel. volume
1.08
Price X volume
3.91M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
AbCellera Biologics Inc | ABCL | Biotechnology | 2.5 | 736.66M | 0.81% | n/a | 6.49% |
Arbutus Biopharma Corporation | ABUS | Biotechnology | 3.84 | 724.92M | -1.54% | n/a | 6.09% |
Erasca Inc. Common Stock | ERAS | Biotechnology | 2.54 | 717.56M | 0.79% | n/a | 11.96% |
Pliant Therapeutics Inc. | PLRX | Biotechnology | 11.53 | 701.04M | 5.68% | n/a | 15.34% |
Terns Pharmaceuticals Inc. | TERN | Biotechnology | 8.27 | 698.29M | 0.85% | n/a | 0.11% |
Mineralys Therapeutics Inc. | MLYS | Biotechnology | 13.88 | 690.21M | 8.44% | n/a | 0.00% |
CureVac N.V | CVAC | Biotechnology | 3.02 | 679.69M | 0.67% | n/a | 10.37% |
Avid Bioservices Inc | CDMO | Biotechnology | 10.63 | 678.14M | -1.02% | n/a | 353.77% |
ORIC Pharmaceuticals Inc | ORIC | Biotechnology | 9.61 | 677.91M | -1.84% | n/a | 0.92% |
ATXS | ATXS | Biotechnology | 11.87 | 669.77M | 2.06% | n/a | 1.67% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Ennis Inc | EBF | Building Products & Equipment | 24.31 | 631.67M | 2.36% | 15.15 | 2.42% |
ACCO Brands Corporation | ACCO | Building Products & Equipment | 5.25 | 502.94M | -0.19% | n/a | 174.23% |
Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 11.63 | 366.05M | 0.00% | 47.92 | 88.92% |
ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 21.28 | 334.47M | -4.23% | n/a | 286.96% |
Marine Products Corporation | MPX | Recreational Vehicles | 9.47 | 328.78M | 0.21% | 13.24 | 0.00% |
MCBC Holdings Inc | MCFT | Recreational Vehicles | 17.64 | 292.95M | -0.56% | 35.53 | 26.82% |
CPI Card Group Inc | PMTS | Building Products & Equipment | 23.62 | 261.38M | 4.61% | 17.90 | -621.78% |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 13.5 | 219.91M | 1.89% | 8.52 | 39.79% |
Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 31.64 | 90.86M | -0.32% | 5.47 | 19.82% |
Saga Communications Inc | SGA | Broadcasting - Radio | 14 | 87.66M | -1.27% | 14.62 | 7.10% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -1.21 | 0.76 | Cheaper |
Ent. to Revenue | 555.68 | 3,674.48 | Cheaper |
PE Ratio | - | 38.01 | - |
Price to Book | 8.10 | 14.10 | Cheaper |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 55.52 | 74.67 | Lower Risk |
Debt to Equity | 0.08 | -1.82 | Expensive |
Debt to Assets | 0.06 | 0.26 | Cheaper |
Market Cap | 676.95M | 3.73B | Emerging |